.
MEDIA CONTACTS:
Katie Edmiston | Marketing Manager | NCODA
Katie.Edmiston@ncoda.org
813-843-1629
Courtney Anderson | Director, Mktg & Patient Growth | Minnesota Oncology
Courtney.Anderson@usoncology.com
612-309-3415
Minnesota Oncology First to Earn NCODA Center of Excellence Medically-Integrated Pharmacy Accreditation
CAZENOVIA, NY – May 12, 2022 – Minnesota Oncology has become the first practice to earn NCODA’s Center of Excellence Medically Integrated Pharmacy Accreditation in the nation. The announcement was made at the recent 2022 NCODA International Spring Forum in front of hundreds of oncology clinical and industry professionals, pinpointing a significant milestone for the new accreditation program and oncology practice.
Elizabeth Bell, Director of Medically Integrated Pharmacy Accreditation for NCODA said, “Minnesota Oncology demonstrates a strong commitment to the highest level of care. This accreditation distinction reflects their focus on patients and prioritization on quality care within a medically-integrated practice.” Patients at Minnesota Oncology are able to receive their medication consistently and timely, allowing for better patient outcomes and provider experience from the first to the last fill. This outcome aligns with the objective the program was built on – to bring sustainability and value for all stakeholders.
“I am incredibly thankful to the entire pharmacy team at Minnesota Oncology for becoming the first accredited NCODA Medically-Integrated Pharmacy in the Nation,” said Minnesota Oncology Director of Pharmacy Services, Paul Foresberg, PharmD, BCOP, MHA. “This accreditation is an outstanding achievement for Minnesota Oncology not only because it highlights the consistent and high-quality pharmaceutical care our team provides, but because of the long term positive impact it will have on our patients. We know that medically-integrated pharmacies provide the best possible patient-centered care, and we believe that this accreditation gives us the opportunity to clearly demonstrate the valuable service we consistently provide.”
This three year accreditation, based on compliance with the ASCO/NCODA Patient-Centered Standards for Medically Integrated Dispensing is the first and only accreditation program designed specifically for medically integrated practices. Unlike other accreditation programs, the CoE MIP Accreditation eliminates clinical fragmentation and administrative burdens, and provides innovative standards and tools specifically designed to improve outcomes, enhance quality of services, and decrease costs.
#####
About NCODA
NCODA is a leading non-profit organization dedicated to empowering medically-integrated oncology practices to deliver positive, patient-centered outcomes by providing leadership, expertise, quality standards, and best practices. For more information about NCODA visit www.ncoda.org or follow @NCODA on LinkedIn.
About Minnesota Oncology
Minnesota Oncology is an independent, community-based cancer care practice providing patient-centered, evidence-based treatment in the Twin Cities metro area. Minnesota Oncology patients have access to more than 100 cancer care experts, evidence-based treatment paths, clinical trials, 12 close-to-home locations and comprehensive services to support the whole person.
Minnesota Oncology is a practice in The US Oncology Network (The Network). The practices in The Network comprise more than 1,380 independent physicians dedicated to delivering value-based, integrated care to patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network is supported by McKesson Corporation, whose coordinated resources and infrastructure allow doctors in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. Minnesota Oncology also participates in clinical trials through US Oncology Research, which has played a role in more than 100 FDA-approved cancer therapies.